Table 2. Characteristics of included... | American Society of Hematology

Table 2.

Characteristics of included studies comparing home vs hospital treatment of patients with low-risk PE

Author, y	Country	Study design	No. of patients	Intervention: home treatment	Control: hospital treatment	Mean hospital length of stay	Mean age ± SD, y	Female, %	Known cancer, %	Duration of follow-up, mo	How was risk of PE complications determined?
Beer et al,²⁴ 2003	Switzerland	Cohort	Home: 43	LMWH for 5-10 d; oral anticoagulation was continued for 6-12 mo; treated at home	LMWH for 5-10 d; oral anticoagulation was continued for 6-12 mo; treated in hospital	Not reported	Median (range): 69 (18-96)	Not reported	Not reported	3	Unvalidated prediction tool
Beer et al,²⁴ 2003	Switzerland	Cohort	Hospital: 62			Not reported	Median (range): 69 (18-96)	Not reported	Not reported	3	Unvalidated prediction tool
Siragusa et al,²⁵ 2005*	Italy	Cohort	Home: 36	LMWH followed by warfarin or with LMWH alone; treated at home	LMWH followed by warfarin or with LMWH alone; treated in hospital	Home: 3.1 h	Not reported for PE sample	Not reported for PE sample	Not reported for PE sample	6	Poor clinical conditions related to concomitant medical disorders, illness that independently required hospitalization, poor compliance, high risk of bleeding or active bleeding, renal insufficiency, acute anemia, pain requiring parenteral narcotics
Siragusa et al,²⁵ 2005*	Italy	Cohort	Hospital: 32			Hospital: 8 ± 2 d	Not reported for PE sample	Not reported for PE sample	Not reported for PE sample	6
Rodriguez-Cerrillo et al,²⁶ 2009†	Spain	Cohort	Home: 30	LMWH followed by warfarin or with LMWH alone; treated at home	LMWH followed by warfarin or with LMWH alone; treated in hospital	Home: 0 d	Median (range):Home: 66.8 (27-91)	Home: 30	Not reported	3	Massive PE, hemodynamic instability, oxygen saturation lower than 92% on room air, heart failure, hemoptysis, arrhythmia, contraindication for LMWH
Rodriguez-Cerrillo et al,²⁶ 2009†	Spain	Cohort	Hospital: 31			Hospital: 10.6 d	Hospital: 66.7 (31-90)	Hospital: 45.2	Not reported	3
Aujesky et al,²² 2011	Switzerland, France, Belgium, US	RCT	Home: 171	LMWH and VKA	LMWH and VKA; admitted to hospital	All patients discharged from ED within 24 h of randomization	Home: 47	50.9	Home: 1	3	PESI
Aujesky et al,²² 2011	Switzerland, France, Belgium, US	RCT	Hospital: 168	LMWH and VKA	LMWH and VKA; admitted to hospital		Hospital: 49	50.9	Hospital: 2	3	PESI
Frank Peacock et al,²³ 2018	US	RCT	Home: 51	Rivaroxaban for 90 d	Standard-of care including bridging therapy or DOAC; admitted to hospital	All patients discharged from ED within 24 h	48.26 ± 15.5	51.8	Home: 6	3	Hestia criteria
Frank Peacock et al,²³ 2018	US	RCT	Hospital: 63	Rivaroxaban for 90 d		All patients discharged from ED within 24 h	48.26 ± 15.5	51.8	Hospital: 6	3	Hestia criteria

Author, y	Country	Study design	No. of patients	Intervention: home treatment	Control: hospital treatment	Mean hospital length of stay	Mean age ± SD, y	Female, %	Known cancer, %	Duration of follow-up, mo	How was risk of PE complications determined?
Beer et al,²⁴ 2003	Switzerland	Cohort	Home: 43	LMWH for 5-10 d; oral anticoagulation was continued for 6-12 mo; treated at home	LMWH for 5-10 d; oral anticoagulation was continued for 6-12 mo; treated in hospital	Not reported	Median (range): 69 (18-96)	Not reported	Not reported	3	Unvalidated prediction tool
Beer et al,²⁴ 2003	Switzerland	Cohort	Hospital: 62			Not reported	Median (range): 69 (18-96)	Not reported	Not reported	3	Unvalidated prediction tool
Siragusa et al,²⁵ 2005*	Italy	Cohort	Home: 36	LMWH followed by warfarin or with LMWH alone; treated at home	LMWH followed by warfarin or with LMWH alone; treated in hospital	Home: 3.1 h	Not reported for PE sample	Not reported for PE sample	Not reported for PE sample	6	Poor clinical conditions related to concomitant medical disorders, illness that independently required hospitalization, poor compliance, high risk of bleeding or active bleeding, renal insufficiency, acute anemia, pain requiring parenteral narcotics
Siragusa et al,²⁵ 2005*	Italy	Cohort	Hospital: 32			Hospital: 8 ± 2 d	Not reported for PE sample	Not reported for PE sample	Not reported for PE sample	6
Rodriguez-Cerrillo et al,²⁶ 2009†	Spain	Cohort	Home: 30	LMWH followed by warfarin or with LMWH alone; treated at home	LMWH followed by warfarin or with LMWH alone; treated in hospital	Home: 0 d	Median (range):Home: 66.8 (27-91)	Home: 30	Not reported	3	Massive PE, hemodynamic instability, oxygen saturation lower than 92% on room air, heart failure, hemoptysis, arrhythmia, contraindication for LMWH
Rodriguez-Cerrillo et al,²⁶ 2009†	Spain	Cohort	Hospital: 31			Hospital: 10.6 d	Hospital: 66.7 (31-90)	Hospital: 45.2	Not reported	3
Aujesky et al,²² 2011	Switzerland, France, Belgium, US	RCT	Home: 171	LMWH and VKA	LMWH and VKA; admitted to hospital	All patients discharged from ED within 24 h of randomization	Home: 47	50.9	Home: 1	3	PESI
Aujesky et al,²² 2011	Switzerland, France, Belgium, US	RCT	Hospital: 168	LMWH and VKA	LMWH and VKA; admitted to hospital		Hospital: 49	50.9	Hospital: 2	3	PESI
Frank Peacock et al,²³ 2018	US	RCT	Home: 51	Rivaroxaban for 90 d	Standard-of care including bridging therapy or DOAC; admitted to hospital	All patients discharged from ED within 24 h	48.26 ± 15.5	51.8	Home: 6	3	Hestia criteria
Frank Peacock et al,²³ 2018	US	RCT	Hospital: 63	Rivaroxaban for 90 d		All patients discharged from ED within 24 h	48.26 ± 15.5	51.8	Hospital: 6	3	Hestia criteria

Siragusa et al²⁵ included patients with PE and DVT and included patients with cancer only.

†

Rodriguez-Cerrillo et al²⁶ were randomized to hospital or home hospital. Home hospital patients were managed in their own homes.

View Large

This Feature Is Available To Subscribers Only